2 completed, 1 recruiting. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow IMADetect®: new trials by email Literature Review of IMADetect® trials Research Report on IMADetect®
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors IMA203 Product, IMA203 product- flat dose, IMA203CD8 Product - Refractory Cancer, Recurrent Cancer | Phase 1 / Phase 2 | Recruiting | Immatics US, Inc. | 375 | 2019-05-14 | 2026-05-13 |
| TCR-engineered T Cells in Solid Tumors: IMA202-101 IMA202 Product, IMADetect® - Solid Tumor, Adult, Refractory Cancer | Phase 1 | Completed | Immatics US, Inc. | 16 | 2019-05-02 | 2025-02-04 |
| TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101) IMA201 Product, IMADetect® - Solid Tumor, Cancer | Phase 1 | Completed | Immatics US, Inc. | 7 | 2018-12-19 | 2025-02-04 |
Neoplasms (3) · Recurrence (2) · Melanoma (1) · Ovarian Neoplasms (1) · Uveal Melanoma (1)
Germany (3) · United States (3)
Cedrik Britten, M.D. (1) · Cedrik Britten, MD (1) · Cedrik Britten, MD, PhD (1)